La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Shandong Xinhua Pharmaceutical Crescita futura
Future criteri di controllo 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Shandong Xinhua Pharmaceutical.
Informazioni chiave
n/a
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
Pharmaceuticals crescita degli utili | 11.5% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | None |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Nessun aggiornamento
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Shandong Xinhua Pharmaceutical non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.
Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.
Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
3/31/2024 | 7,936 | 487 | 166 | 487 | N/A |
12/31/2023 | 8,101 | 497 | -60 | 265 | N/A |
9/30/2023 | 8,547 | 510 | 349 | 601 | N/A |
6/30/2023 | 8,511 | 486 | 337 | 584 | N/A |
3/31/2023 | 8,311 | 454 | 353 | 592 | N/A |
1/1/2023 | 7,503 | 411 | 513 | 758 | N/A |
9/30/2022 | 7,073 | 357 | 5 | 263 | N/A |
6/30/2022 | 6,673 | 343 | 32 | 289 | N/A |
3/31/2022 | 6,623 | 357 | -107 | 152 | N/A |
12/31/2021 | 6,560 | 349 | 10 | 259 | N/A |
9/30/2021 | 6,307 | 364 | -19 | 248 | N/A |
6/30/2021 | 6,271 | 353 | 107 | 385 | N/A |
3/31/2021 | 6,068 | 339 | 123 | 405 | N/A |
12/31/2020 | 6,006 | 325 | 140 | 420 | N/A |
9/30/2020 | 5,814 | 305 | 208 | 453 | N/A |
6/30/2020 | 5,769 | 323 | 75 | 392 | N/A |
3/31/2020 | 5,682 | 310 | 69 | 399 | N/A |
12/31/2019 | 5,606 | 300 | -18 | 348 | N/A |
9/30/2019 | 5,716 | 303 | 3 | 480 | N/A |
6/30/2019 | 5,680 | 281 | -85 | 344 | N/A |
3/31/2019 | 5,457 | 264 | -26 | 382 | N/A |
12/31/2018 | 5,245 | 255 | -65 | 324 | N/A |
9/30/2018 | 5,023 | 229 | 60 | 339 | N/A |
6/30/2018 | 4,800 | 226 | 281 | 517 | N/A |
3/31/2018 | 4,638 | 226 | 142 | 332 | N/A |
12/31/2017 | 4,516 | 210 | N/A | 390 | N/A |
9/30/2017 | 4,491 | 207 | N/A | 391 | N/A |
6/30/2017 | 4,420 | 183 | N/A | 365 | N/A |
3/31/2017 | 4,306 | 154 | N/A | 446 | N/A |
12/31/2016 | 4,015 | 122 | N/A | 439 | N/A |
9/30/2016 | 3,800 | 110 | N/A | 388 | N/A |
6/30/2016 | 3,647 | 103 | N/A | 359 | N/A |
3/31/2016 | 3,602 | 89 | N/A | 414 | N/A |
12/31/2015 | 3,597 | 83 | N/A | 349 | N/A |
9/30/2015 | 3,604 | 64 | N/A | 304 | N/A |
6/30/2015 | 3,678 | 36 | N/A | 284 | N/A |
3/31/2015 | 3,653 | 62 | N/A | 266 | N/A |
12/31/2014 | 3,590 | 51 | N/A | 346 | N/A |
9/30/2014 | 3,769 | 52 | N/A | N/A | N/A |
6/30/2014 | 3,635 | 74 | N/A | 235 | N/A |
3/31/2014 | 3,588 | 50 | N/A | 290 | N/A |
12/31/2013 | 3,391 | 39 | N/A | 105 | N/A |
9/30/2013 | 3,073 | 27 | N/A | N/A | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if 719's forecast earnings growth is above the savings rate (2.3%).
Guadagni vs Mercato: Insufficient data to determine if 719's earnings are forecast to grow faster than the Hong Kong market
Guadagni ad alta crescita: Insufficient data to determine if 719's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if 719's revenue is forecast to grow faster than the Hong Kong market.
Ricavi ad alta crescita: Insufficient data to determine if 719's revenue is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if 719's Return on Equity is forecast to be high in 3 years time